Ann: Positive Preliminary Results from Adult Clinical Study-RAP.AX, page-285

From The Australian


ResApp (RAP) 43c

We wouldn’t wear this as a badge of honour, but the app-based respiratory house was one of the most talked-about stocks on the Hot Copper tattle site ahead of yesterday’s much-anticipated clinical results.

Mirroring an early paediatric trial, a subset of the 322-patient adult study showed ResApp’s algorithmic tool to be highly accurate in identifying disorders such as asthma and pneumonia — more so than the trusted stethoscope. ResApp’s next step is a similar cough-into-the-app trial at a US hospital site, ahead of applying for Food and Drug Administration marketing approval.

With online GP consultations booming, ResApp plans to strike a deal with a US telehealth provider. According to Deloitte, 75 million online consultations took place in 2014 and this rate is expected to double by 2017.

About one-third of these cyber-visits are for respiratory visits, but without a diagnosis tool the best the online docs advise is “you had better see a real doctor’’.

We’ll stick with a spec buy despite the hefty $280m valuation and the prospect of the Hot Copper crowd taking profits.

The Australian accepts no responsibility for stock recommendations. Readers should contact a licensed financial adviser. The author holds BHP shares